Clinical Trial Update: Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating obinutuzumab as induction therapy for remission in relapsing PR3-ANCA granulomatosis with polyangiitis is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Granulomatosis With Polyangiitis | Phase 2 | Status: RECRUITING